1. Home
  2. CMMB vs HUBC Comparison

CMMB vs HUBC Comparison

Compare CMMB & HUBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMMB
  • HUBC
  • Stock Information
  • Founded
  • CMMB 2004
  • HUBC 2017
  • Country
  • CMMB Israel
  • HUBC Israel
  • Employees
  • CMMB N/A
  • HUBC N/A
  • Industry
  • CMMB Biotechnology: Pharmaceutical Preparations
  • HUBC
  • Sector
  • CMMB Health Care
  • HUBC
  • Exchange
  • CMMB Nasdaq
  • HUBC Nasdaq
  • Market Cap
  • CMMB 22.0M
  • HUBC 19.3M
  • IPO Year
  • CMMB N/A
  • HUBC N/A
  • Fundamental
  • Price
  • CMMB $1.13
  • HUBC $2.99
  • Analyst Decision
  • CMMB Strong Buy
  • HUBC
  • Analyst Count
  • CMMB 2
  • HUBC 0
  • Target Price
  • CMMB $8.50
  • HUBC N/A
  • AVG Volume (30 Days)
  • CMMB 187.2K
  • HUBC 1.9M
  • Earning Date
  • CMMB 08-20-2025
  • HUBC 05-01-2025
  • Dividend Yield
  • CMMB N/A
  • HUBC N/A
  • EPS Growth
  • CMMB N/A
  • HUBC N/A
  • EPS
  • CMMB N/A
  • HUBC N/A
  • Revenue
  • CMMB N/A
  • HUBC $29,562,000.00
  • Revenue This Year
  • CMMB N/A
  • HUBC N/A
  • Revenue Next Year
  • CMMB N/A
  • HUBC N/A
  • P/E Ratio
  • CMMB N/A
  • HUBC N/A
  • Revenue Growth
  • CMMB N/A
  • HUBC N/A
  • 52 Week Low
  • CMMB $0.87
  • HUBC $1.72
  • 52 Week High
  • CMMB $2.55
  • HUBC $14.00
  • Technical
  • Relative Strength Index (RSI)
  • CMMB 42.55
  • HUBC 70.62
  • Support Level
  • CMMB $1.17
  • HUBC $1.98
  • Resistance Level
  • CMMB $1.23
  • HUBC $3.44
  • Average True Range (ATR)
  • CMMB 0.05
  • HUBC 0.24
  • MACD
  • CMMB 0.00
  • HUBC 0.13
  • Stochastic Oscillator
  • CMMB 34.11
  • HUBC 74.05

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

About HUBC Hub Cyber Security Ltd.

Hub Cyber Security Ltd is engaged in the development of cyber products, software, quality systems, reliability, and risk management. It operates in several countries and provides cybersecurity computing appliances as well as a wide range of cybersecurity professional services. The company has two operating segments: the Product and Technology Segment, and the Professional Services Segment. The majority of its revenue comes from the professional services segment, which provides data and cybersecurity, system security and reliability solutions, as well as related services such as consulting, planning, training, integration, and ongoing servicing of cybersecurity, risk management, system quality, reliability, and security projects, including fully managed corporate cybersecurity services.

Share on Social Networks: